CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,141,767 | -61.6% | 104,271 | -69.4% | 0.01% | -62.5% |
| Q1 2023 | $2,970,363 | +63.3% | 340,638 | +17.4% | 0.02% | +60.0% |
| Q4 2022 | $1,819,391 | +96.1% | 290,174 | +9.5% | 0.01% | +66.7% |
| Q3 2022 | $928,000 | +115.8% | 265,062 | +81.7% | 0.01% | +100.0% |
| Q2 2022 | $430,000 | +105.7% | 145,913 | +117.1% | 0.00% | +200.0% |
| Q1 2022 | $209,000 | -59.0% | 67,221 | -24.3% | 0.00% | -66.7% |
| Q4 2020 | $510,000 | -61.8% | 88,837 | -51.8% | 0.00% | -66.7% |
| Q3 2020 | $1,335,000 | +56.0% | 184,394 | -24.8% | 0.01% | +50.0% |
| Q2 2020 | $856,000 | +394.8% | 245,330 | +110.4% | 0.01% | +200.0% |
| Q1 2020 | $173,000 | +220.4% | 116,575 | +321.6% | 0.00% | – |
| Q4 2019 | $54,000 | – | 27,650 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |